ARTEMISMED
Artemis Med Service
Artemis Med Service (ARTEMISMED) Stock Analysis & Case Study
Is ARTEMISMED a good buy? The data-driven verdict.
Artemis Med Service (ARTEMISMED) trades at ₹268,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Artemis Med Service (ARTEMISMED) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 40.1× earnings, ROE of 12.0%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ARTEMISMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ARTEMISMED overvalued? ARTEMISMED P/E vs its sector
ARTEMISMED's P/E of 40.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.17% dividend yield is below the peer median of 1.65%.
The bull case for ARTEMISMED
- A healthy 12.0% return on equity.
The bear case & risks
- A rich 40.1× P/E leaves a thin margin of safety if growth slows.
ARTEMISMED Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ARTEMISMED scores 4/9,mixed financial health.
ARTEMISMED MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ARTEMISMED with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 32.9% | 3.0× |
| Dhan | 49.0% | 2.0× |
Compare every broker on the ARTEMISMED MTF page.
ARTEMISMED vs peers,sector comparison
About Artemis Med Service: sector, index & market-cap context
Artemis Med Service (ARTEMISMED) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹4,247 Cr. See more Nifty 500 stocks.
How the ARTEMISMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Artemis Med Service's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ARTEMISMED analysis, FAQs
Is Artemis Med Service (ARTEMISMED) a good buy?
On the numbers, Artemis Med Service (ARTEMISMED) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 40.1× earnings, ROE of 12.0%. This is a data snapshot for research, not investment advice.
Is ARTEMISMED overvalued or undervalued?
ARTEMISMED trades at 40.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the bull case for ARTEMISMED?
A healthy 12.0% return on equity.
What are the risks in ARTEMISMED?
A rich 40.1× P/E leaves a thin margin of safety if growth slows.